Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of BioAtla's Evalstotug?
Evalstotug is a monoclonal antibody commercialized by BioAtla, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Evalstotug by BioAtla for Melanoma: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
Evalstotug by BioAtla for Uveal Melanoma: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...
Evalstotug by BioAtla for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Evalstotug by BioAtla for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Evalstotug is under clinical development by BioAtla and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...